Jean-Michel Molina

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

Bonaventura Clotet, A. LaMarca, B. Clotet, 2012, The Lancet. Infectious diseases.

Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)

Roland Tubiana, Vincent Calvez, Christine Katlama, 2004, AIDS.

Minor HIV-1 Variants with the K103N Resistance Mutation during Intermittent Efavirenz-Containing Antiretroviral Therapy and Virological Failure

Florence Nicot, Jacques Izopet, Jean-Pierre Aboulker, 2011, PloS one.

Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome

M. Robin, G. Socié, E. Gluckman, 2007, Haematologica.

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

David Thompson, Laurence Meyer, Jean-Pierre Aboulker, 2015, The New England journal of medicine.

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients

Beatriz Grinsztejn, K. Ruxrungtham, P. Cahn, 2011, AIDS.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

Huldrych F. Günthard, Michael S. Saag, Joseph J. Eron, 2018, JAMA.

High Burden of Non-Influenza Viruses in Influenza-Like Illness in the Early Weeks of H1N1v Epidemic in France

François Simon, Matthieu Resche-Rigon, P. Taboulet, 2011, PloS one.